This Biotech Company Is Building a Global Cannabinoid Business
Exclusive Interview with 22nd Century Group CEO Jim Mish 22nd Century Group (NASDAQ: XXII) is a plant-based biotechnology that operates three business segments: tobacco, cannabis/hemp and hops. The company...